Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (ATR) delivers innovative dispensing systems and packaging solutions for pharmaceutical, beauty, and consumer goods markets worldwide. This page provides centralized access to official company announcements, financial updates, and industry developments.
Investors and stakeholders will find timely updates including earnings reports, product innovations, and strategic partnerships. Our curated news collection simplifies tracking regulatory milestones and market trends impacting AptarGroup's core segments: Pharma, Beauty, and Closures.
All content is sourced from verified corporate communications and reputable financial publications. Bookmark this page for efficient monitoring of ATR's operational developments, sustainability initiatives, and leadership changes within the global packaging industry.
AptarGroup reported robust fourth quarter and annual results for 2021, showcasing a 9% increase in reported sales and a 10% rise in core sales. Annual sales reached a record $3.2 billion, with reported earnings per share climbing 12% to $3.61. The company made strategic acquisitions, including Voluntis and part of Weihai Hengyu Medical Products, enhancing its digital therapeutic and injectable drug delivery capabilities. Despite increased input costs impacting margins, Aptar's commitment to sustainability and cash dividends remains strong, concluding 2021 with $99 million in dividends.
AptarGroup, Inc. (NYSE: ATR) has achieved a Platinum rating from EcoVadis, recognizing its sustainability efforts and placing it in the top 1% of 85,000 companies rated globally. This achievement reflects significant progress from Bronze to Gold and now to Platinum over the last eight years. The rating assesses performance across themes such as environment, labor and human rights, ethics, and sustainable procurement. Aptar’s commitment to sustainability aligns with partners like the Ellen MacArthur Foundation and the United Nations Global Compact.
AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, payable on February 23, 2022, with a record date of February 3, 2022. The company will host a conference call on February 18, 2022, at 8:00 a.m. CT to discuss its fourth quarter and year-end results for 2021. Additionally, the 2022 Annual Meeting of Stockholders is scheduled for May 4, 2022, at 9:00 a.m. CT, with a record date for voting set for March 11, 2022.
AptarGroup, Inc. (NYSE: ATR) announced the schedule for its quarterly conference calls for the year 2022, with press releases issued after trading hours. Key dates include:
- 4th Quarter and Annual Results: February 17, 2022, with a call on February 18, 2022, at 8:00 a.m. CT
- 1st Quarter Results: April 28, 2022, with a call on April 29, 2022, at 8:00 a.m. CT
- 2nd Quarter Results: July 28, 2022, with a call on July 29, 2022, at 8:00 a.m. CT
- 3rd Quarter Results: October 27, 2022, with a call on October 28, 2022, at 8:00 a.m. CT
AptarGroup, Inc. (NYSE: ATR) has been recognized as the top company on Forbes' inaugural Green Growth 50 list for 2021. This accolade highlights Aptar's commitment to reducing greenhouse gas emissions while achieving earnings growth. Aptar aims to have over 60% of its facilities certified as Landfill Free by year-end and emphasizes the importance of sustainable solutions in its business strategies. The company focuses on recyclability, renewable energy, and sustainable product design in collaboration with organizations like the Ellen MacArthur Foundation.
AptarGroup, Inc. (NYSE:ATR) reported a 9% increase in Q3 2021 sales, reaching $825 million, mainly from strong performance in Beauty + Home and Food + Beverage. Adjusted earnings per share (EPS) were $0.94, down from $1.01 a year ago, due to restructuring and investment losses. The Pharma segment experienced slight sales declines, impacted by lower demand in prescription markets. The company completed acquisitions enhancing its capabilities in medical and digital solutions. Looking ahead, EPS is projected between $0.88 and $0.96 for Q4, with focus on cost containment amid rising inflation.